These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity. Mangsbo SM; Broos S; Fletcher E; Veitonmäki N; Furebring C; Dahlén E; Norlén P; Lindstedt M; Tötterman TH; Ellmark P Clin Cancer Res; 2015 Mar; 21(5):1115-26. PubMed ID: 25316820 [TBL] [Abstract][Full Text] [Related]
3. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer. Fransen MF; Cordfunke RA; Sluijter M; van Steenbergen MJ; Drijfhout JW; Ossendorp F; Hennink WE; Melief CJ Vaccine; 2014 Mar; 32(15):1654-60. PubMed ID: 24508038 [TBL] [Abstract][Full Text] [Related]
5. Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model. Khong A; Brown MD; Vivian JB; Robinson BW; Currie AJ J Immunother; 2013 Sep; 36(7):365-72. PubMed ID: 23924788 [TBL] [Abstract][Full Text] [Related]
6. Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles. Broos S; Sandin LC; Apel J; Tötterman TH; Akagi T; Akashi M; Borrebaeck CA; Ellmark P; Lindstedt M Biomaterials; 2012 Sep; 33(26):6230-9. PubMed ID: 22687756 [TBL] [Abstract][Full Text] [Related]
7. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767 [TBL] [Abstract][Full Text] [Related]
8. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects. Welniak LA; Shorts L; Subleski J; Blazar BR; Wiltrout RH; Murphy WJ Biol Blood Marrow Transplant; 2004 Aug; 10(8):534-9. PubMed ID: 15282531 [TBL] [Abstract][Full Text] [Related]
9. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40. Khong A; Cleaver AL; Fahmi Alatas M; Wylie BC; Connor T; Fisher SA; Broomfield S; Lesterhuis WJ; Currie AJ; Lake RA; Robinson BW BMC Cancer; 2014 Dec; 14():969. PubMed ID: 25518732 [TBL] [Abstract][Full Text] [Related]
10. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300 [TBL] [Abstract][Full Text] [Related]
11. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031 [TBL] [Abstract][Full Text] [Related]
12. Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1. Liu HC; Viswanath DI; Pesaresi F; Xu Y; Zhang L; Di Trani N; Paez-Mayorga J; Hernandez N; Wang Y; Erm DR; Ho J; Susnjar A; Liu X; Demaria S; Chen SH; Teh BS; Butler EB; Xuan Chua CY; Grattoni A Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):492-506. PubMed ID: 32768562 [TBL] [Abstract][Full Text] [Related]
13. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010 [TBL] [Abstract][Full Text] [Related]
14. Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14. Francisco JA; Donaldson KL; Chace D; Siegall CB; Wahl AF Cancer Res; 2000 Jun; 60(12):3225-31. PubMed ID: 10866315 [TBL] [Abstract][Full Text] [Related]
15. Role of the endogenous production of interleukin 12 in immunotherapy. Harada M; Tamada K; Abe K; Yasumoto K; Kimura G; Nomoto K Cancer Res; 1998 Jul; 58(14):3073-7. PubMed ID: 9679973 [TBL] [Abstract][Full Text] [Related]
16. Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors. Cozza EM; Cooper TK; Budgeon LR; Christensen ND; Schell TD Cancer Immunol Immunother; 2015 Mar; 64(3):325-36. PubMed ID: 25408469 [TBL] [Abstract][Full Text] [Related]
17. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. van Mierlo GJ; den Boer AT; Medema JP; van der Voort EI; Fransen MF; Offringa R; Melief CJ; Toes RE Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5561-6. PubMed ID: 11929985 [TBL] [Abstract][Full Text] [Related]
18. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models. Shoji T; Saito R; Chonan M; Shibahara I; Sato A; Kanamori M; Sonoda Y; Kondo T; Ishii N; Tominaga T Neuro Oncol; 2016 Aug; 18(8):1120-8. PubMed ID: 26917236 [TBL] [Abstract][Full Text] [Related]
19. Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases. von Scheidt B; Leung PS; Yong MC; Zhang Y; Towne JE; Smyth MJ; Teng MW Cancer Res; 2014 May; 74(9):2412-21. PubMed ID: 24556719 [TBL] [Abstract][Full Text] [Related]
20. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]